The search for small molecules that might act upstream of the GPR56‐associated network led us to the CDK7/12/13 inhibitor THZ1, as it had been shown to overcome resistance to SMO antagonists in medulloblastoma by acting upstream and independent of SMO (Liu et al, 2019). Here, CDK7 is linked to medulloblastoma.